Skip to main content

Advertisement

Table 2 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients with low (<8 %) and high (≥8 %) baseline HbA1c levels

From: Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

Outcome Effect estimate 95 % Confidence limits p value Effect estimate 95 % Confidence limits p value
Lower Upper Lower Upper
Low (<8 %) baseline HbA1c High (≥8 %) baseline HbA1c  
Change in HbA1c (%) −0.80 −1.18 −0.43 <0.0001 −1.19 −1.46 −0.92 <0.0001
Change in weight (kg) −0.62 −1.72 0.49 0.28 −0.17 −0.68 0.34 0.52
Change in FPG (mg/dL) −12.5 −30.9 5.8 0.18 −14.7 −25.9 −3.6 0.0097
Change in PPG: meal test (mg/dL) −132.0 −171.7 −92.4 <0.0001 −162.0 −185.9 −138.1 <0.0001
  1. FPG fasting plasma glucose, PPG postprandial glucose
  Odds ratio 95 % Confidence limits p value Odds ratio 95 % Confidence limits p value
Lower Upper Lower Upper
Low (<8 %) baseline HbA1c High (≥8 %) baseline HbA1c
Symptomatic hypoglycemia 2.9 0.8 10.0 0.10 2.9 1.2 7.1 0.0229
Severe hypoglycemia 0.0 0.0 0.0 0.0 0.0 0.0
Endpoint HbA1c <7 % 25.5 5.2 124.6 <0.0001 15.8 2.9 85.6 0.0014
Endpoint HbA1c <7 % and no weight gain 15.8 3.3 75.8 0.0005 10.0 1.8 55.9 0.0091
Endpoint HbA1c <7 % and no symptomatic hypoglycemia 11.8 2.0 68.7 0.0060 11.1 2.0 61.8 0.0059
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia 8.9 1.5 52.2 0.0154 6.4 1.1 38.6 0.0430
  1. FPG fasting plasma glucose, PPG postprandial glucose